Antibody constructs for DLL3 and CD3

US11591396B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Tobias Raum · Munich, DE
• Claudia Blümel · Munich, DE
• Christoph Dahlhoff · Munich, DE
• Patrick Hoffmann · Munich, DE
• Peter Kufer · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Elisabeth Nahrwold · Munich, DE
• Jochen Pendzialek · Munich, DE

Key dates

• Filing date: May 6, 2020
• Grant date: Feb 28, 2023
• Expiry date: Nov 27, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.